Sign In
Buy BIO
$301.70
-0.200 (-0.0662%)
At Close: Jul 21, 2026
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
12:02pm, Tuesday, 19'th Apr 2022
Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.
Bio-Rad to Report First-Quarter Financial Results, Thursday, April 28, 2022
08:00am, Monday, 18'th Apr 2022
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fir
Illumina (ILMN) Launches Genomic Solution Hub in Brazil
02:10pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
Illumina's (ILMN) customers and partners in Brazil currently span basic research, applied markets to clinical labs and healthcare institutions.
Here's Why You Should Retain SmileDirectClub (SDC) For Now
01:04pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
Investors are optimistic about SmileDirectClub's (SDC) series of cutting-edge innovation, strategic distribution and insurance partnerships.
Bruker (BRKR) Unveils New Imaging Tools for Cancer Research
12:54pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
Bruker's (BRKR) latest innovation for cancer research is likely to strengthen the company's opportunities in proteomics and spatial biology.
Alcon (ALC) Stock Rallies 4.7% Since Posting Q4 Earnings Beat
02:36pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Alcon (ALC) stock rallies on robust growth across all Surgical and Vision Care sales categories.
Here's Why You Should Hold on to Walgreens Boots (WBA) For Now
04:58pm, Monday, 11'th Apr 2022 Zacks Investment Research
Investors are optimistic about Walgreens (WBA) owing to the recent product launches.
Henry Schein (HSIC) Hits a New 52-Week High: What's Driving It?
12:50pm, Monday, 11'th Apr 2022 Zacks Investment Research
Investors are optimistic about Henry Schein (HSIC) owing to favorable dental business trends and a strong solvency position.
Here's Why You Should Hold on to Chemed (CHE) Stock For Now
03:18pm, Thursday, 07'th Apr 2022 Zacks Investment Research
Investors are optimistic about robust performance by Chemed's (CHE) Roto-Rooter arm.
Walgreens (WBA) Expands Medical Care Offerings in California
01:31pm, Thursday, 07'th Apr 2022 Zacks Investment Research
Walgreens' (WBA) new initiative is intended to reduce care gaps and advance care management by providing access to more affordable and convenient services.
Bruker (BRKR) to Support Biopharma Industries With New Buyout
01:25pm, Wednesday, 06'th Apr 2022 Zacks Investment Research
Bruker's (BRKR) recent buyout strengthens the company as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies.
Medtronic (MDT) Innovations Aid Global Growth, Volume Woe Stays
01:09pm, Tuesday, 05'th Apr 2022 Zacks Investment Research
In the neuroscience portfolio, Medtronic (/MDT) is gaining market share in Cranial and Spinal technologies.
Abbott (ABT) Aveir VR Leadless Pacemaker Receives FDA Nod
12:57pm, Tuesday, 05'th Apr 2022 Zacks Investment Research
Abbott's (ABT) Aveir VR is a leadless pacemaker designed to treat patients with slow heart rhythms in the United States.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
01:52pm, Monday, 04'th Apr 2022 Zacks Investment Research
Investors are optimistic about STERIS (STE) on impressive growth across its operating segments.
Here's Why You Should Retain CVS Health (CVS) Stock For Now
01:51pm, Monday, 04'th Apr 2022 Zacks Investment Research
Investors are optimistic about CVS Health (CVS) owing to continued progress in its consumer-centric digital solutions.
